Medical Properties Trust Inc has a consensus price target of $9.33 based on the ratings of 20 analysts. The high is $18 issued by Keybanc on July 7, 2022. The low is $4 issued by Truist Securities on December 19, 2024. The 3 most-recent analyst ratings were released by Exane BNP Paribas, RBC Capital, and Wells Fargo on March 12, 2025, March 10, 2025, and March 10, 2025, respectively. With an average price target of $6.33 between Exane BNP Paribas, RBC Capital, and Wells Fargo, there's an implied 16.53% upside for Medical Properties Trust Inc from these most-recent analyst ratings.
1calculated from analyst ratings
Buy Now | Get Alert | |||||||
---|---|---|---|---|---|---|---|---|
03/12/2025 | Buy Now | 65.59% | Exane BNP Paribas | Nate Crossett53% | $5 → $9 | Upgrade | Neutral → Outperform | Get Alert |
03/10/2025 | Buy Now | -8% | RBC Capital | Michael Carroll64% | $4 → $5 | Maintains | Sector Perform | Get Alert |
03/10/2025 | Buy Now | -8% | Wells Fargo | Connor Siversky70% | $4 → $5 | Maintains | Underweight | Get Alert |
12/19/2024 | Buy Now | -26.4% | Truist Securities | Michael Lewis69% | $6 → $4 | Maintains | Hold | Get Alert |
12/05/2024 | Buy Now | -8% | Mizuho | Vikram Malhotra55% | $6 → $5 | Maintains | Neutral | Get Alert |
09/13/2024 | Buy Now | 10.4% | Truist Securities | Michael Lewis69% | $5 → $6 | Maintains | Hold | Get Alert |
09/13/2024 | Buy Now | 19.6% | Colliers Securities | David Toti42% | → $6.5 | Upgrade | Neutral → Buy | Get Alert |
07/02/2024 | Buy Now | -26.4% | Exane BNP Paribas | Nate Crossett53% | $6 → $4 | Downgrade | Outperform → Neutral | Get Alert |
05/30/2024 | Buy Now | -8% | Truist Securities | Michael Lewis69% | $4.5 → $5 | Maintains | Hold | Get Alert |
05/14/2024 | Buy Now | -8% | RBC Capital | Michael Carroll64% | → $5 | Downgrade | Outperform → Sector Perform | Get Alert |
04/17/2024 | Buy Now | -8% | Deutsche Bank | Omotayo Okusanya62% | $2 → $5 | Upgrade | Sell → Hold | Get Alert |
04/15/2024 | Buy Now | -8% | Colliers Securities | David Toti42% | $4.25 → $5 | Maintains | Neutral | Get Alert |
04/08/2024 | Buy Now | -17.2% | Truist Securities | Michael Lewis69% | $4 → $4.5 | Maintains | Hold | Get Alert |
03/01/2024 | Buy Now | 10.4% | Exane BNP Paribas | Nate Crossett53% | → $6 | Upgrade | Neutral → Outperform | Get Alert |
02/20/2024 | Buy Now | -8% | RBC Capital | Michael Carroll64% | $8 → $5 | Maintains | Outperform | Get Alert |
01/30/2024 | Buy Now | -63.2% | Deutsche Bank | Omotayo Okusanya62% | → $2 | Initiates | → Sell | Get Alert |
01/05/2024 | Buy Now | — | Keybanc | Austin Wurschmidt57% | — | Downgrade | Overweight → Sector Weight | Get Alert |
01/03/2024 | Buy Now | 28.79% | Mizuho | Vikram Malhotra55% | $9 → $7 | Maintains | Neutral | Get Alert |
11/29/2023 | Buy Now | -8% | JP Morgan | Michael Lapides62% | $8 → $5 | Maintains | Underweight | Get Alert |
11/10/2023 | Buy Now | -17.2% | Stifel | Stephen Manaker46% | $12 → $4.5 | Downgrade | Buy → Hold | Get Alert |
10/17/2023 | Buy Now | -26.4% | Wells Fargo | Connor Siversky70% | $7 → $4 | Maintains | Underweight | Get Alert |
10/16/2023 | Buy Now | -26.4% | Wells Fargo | Connor Siversky70% | → $4 | Downgrade | Equal-Weight → Underweight | Get Alert |
09/25/2023 | Buy Now | 83.99% | RBC Capital | Michael Carroll64% | → $10 | Reiterates | Outperform → Outperform | Get Alert |
08/31/2023 | Buy Now | 65.59% | Mizuho | Vikram Malhotra55% | $18 → $9 | Downgrade | Buy → Neutral | Get Alert |
08/22/2023 | Buy Now | 83.99% | Barclays | Steve Valiquette54% | $12 → $10 | Maintains | Overweight | Get Alert |
08/21/2023 | Buy Now | 28.79% | JP Morgan | Michael Lapides62% | $9 → $7 | Downgrade | Neutral → Underweight | Get Alert |
08/14/2023 | Buy Now | 83.99% | RBC Capital | Michael Carroll64% | $12 → $10 | Maintains | Outperform | Get Alert |
08/11/2023 | Buy Now | 47.19% | B of A Securities | Joshua Dennerlein50% | $9 → $8 | Downgrade | Neutral → Underperform | Get Alert |
08/11/2023 | Buy Now | — | Raymond James | Jonathan Hughes67% | — | Downgrade | Strong Buy → Underperform | Get Alert |
06/23/2023 | Buy Now | 83.99% | Truist Securities | Michael Lapides62% | $9 → $10 | Maintains | Hold | Get Alert |
04/20/2023 | Buy Now | 65.59% | Wells Fargo | Connor Siversky70% | → $9 | Initiates | → Equal-Weight | Get Alert |
04/19/2023 | Buy Now | 65.59% | Wells Fargo | Connor Siversky70% | → $9 | Initiates | → Equal-Weight | Get Alert |
04/05/2023 | Buy Now | 120.79% | Barclays | Steve Valiquette54% | $14 → $12 | Maintains | Overweight | Get Alert |
04/04/2023 | Buy Now | 175.99% | Keybanc | Austin Wurschmidt57% | $16 → $15 | Maintains | Overweight | Get Alert |
03/31/2023 | Buy Now | 65.59% | Truist Securities | Michael Lapides62% | $8 → $9 | Maintains | Hold | Get Alert |
03/29/2023 | Buy Now | 47.19% | Truist Securities | Michael Lewis69% | $14 → $8 | Maintains | Hold | Get Alert |
03/16/2023 | Buy Now | 83.99% | B of A Securities | Joshua Dennerlein50% | → $10 | Downgrade | Buy → Neutral | Get Alert |
03/07/2023 | Buy Now | 102.39% | Credit Suisse | Omotayo Okusanya62% | → $11 | Reiterates | → Neutral | Get Alert |
03/03/2023 | Buy Now | 120.79% | JP Morgan | Michael Lapides62% | $14 → $12 | Maintains | Neutral | Get Alert |
03/02/2023 | Buy Now | 194.39% | Raymond James | Jonathan Hughes67% | $18 → $16 | Maintains | Strong Buy | Get Alert |
02/27/2023 | Buy Now | 157.59% | Barclays | Steven Valiquette58% | $17 → $14 | Maintains | Overweight | Get Alert |
02/24/2023 | Buy Now | 102.39% | Credit Suisse | Omotayo Okusanya62% | $13 → $11 | Maintains | Neutral | Get Alert |
01/27/2023 | Buy Now | 212.79% | Barclays | Steve Valiquette54% | $19 → $17 | Maintains | Overweight | Get Alert |
01/19/2023 | Buy Now | 194.39% | Keybanc | Austin Wurschmidt57% | $18 → $16 | Maintains | Overweight | Get Alert |
01/17/2023 | Buy Now | 139.19% | Credit Suisse | Omotayo Okusanya62% | $11 → $13 | Maintains | Neutral | Get Alert |
12/21/2022 | Buy Now | 102.39% | Credit Suisse | Omotayo Okusanya62% | $17 → $11 | Maintains | Neutral | Get Alert |
11/14/2022 | Buy Now | 194.39% | B of A Securities | Joshua Dennerlein50% | → $16 | Upgrade | Neutral → Buy | Get Alert |
10/21/2022 | Buy Now | 249.59% | Barclays | Steve Valiquette54% | $23 → $19 | Maintains | Overweight | Get Alert |
10/04/2022 | Buy Now | 231.19% | RBC Capital | Michael Carroll64% | $20 → $18 | Maintains | Outperform | Get Alert |
09/22/2022 | Buy Now | 231.19% | Raymond James | Jonathan Hughes67% | $20 → $18 | Maintains | Strong Buy | Get Alert |
09/16/2022 | Buy Now | 175.99% | Deutsche Bank | Derek Johnston54% | $17 → $15 | Maintains | Hold | Get Alert |
08/04/2022 | Buy Now | 323.18% | Barclays | Steve Valiquette54% | $27 → $23 | Maintains | Overweight | Get Alert |
07/29/2022 | Buy Now | 267.99% | Mizuho | Vikram Malhotra55% | $26 → $20 | Maintains | Buy | Get Alert |
07/15/2022 | Buy Now | 267.99% | Raymond James | Jonathan Hughes67% | $24 → $20 | Maintains | Strong Buy | Get Alert |
07/14/2022 | Buy Now | 212.79% | Credit Suisse | Omotayo Okusanya62% | $23 → $17 | Downgrade | Outperform → Neutral | Get Alert |
07/13/2022 | Buy Now | 212.79% | Deutsche Bank | Derek Johnston54% | $20 → $17 | Maintains | Hold | Get Alert |
07/07/2022 | Buy Now | 231.19% | Keybanc | Josh Beck77% | $23 → $18 | Maintains | Overweight | Get Alert |
06/30/2022 | Buy Now | 175.99% | Jefferies | Jonathan Petersen61% | $19 → $15 | Maintains | Hold | Get Alert |
06/22/2022 | Buy Now | 231.19% | JP Morgan | Michael Mueller54% | $24 → $18 | Downgrade | Overweight → Neutral | Get Alert |
05/20/2022 | Buy Now | 304.78% | RBC Capital | Michael Carroll64% | $25 → $22 | Maintains | Outperform | Get Alert |
05/10/2022 | Buy Now | 341.58% | Raymond James | Jonathan Hughes67% | $26 → $24 | Maintains | Strong Buy | Get Alert |
05/02/2022 | Buy Now | 323.18% | Credit Suisse | Omotayo Okusanya62% | $26 → $23 | Maintains | Outperform | Get Alert |
04/27/2022 | Buy Now | 267.99% | Deutsche Bank | Derek Johnston54% | $25 → $20 | Maintains | Hold | Get Alert |
04/27/2022 | Buy Now | 323.18% | Keybanc | Austin Wurschmidt57% | $24 → $23 | Maintains | Overweight | Get Alert |
The latest price target for Medical Properties Trust (NYSE:MPW) was reported by Exane BNP Paribas on March 12, 2025. The analyst firm set a price target for $9.00 expecting MPW to rise to within 12 months (a possible 65.59% upside). 10 analyst firms have reported ratings in the last year.
The latest analyst rating for Medical Properties Trust (NYSE:MPW) was provided by Exane BNP Paribas, and Medical Properties Trust upgraded their outperform rating.
The last upgrade for Medical Properties Trust Inc happened on March 12, 2025 when Exane BNP Paribas raised their price target to $9. Exane BNP Paribas previously had a neutral for Medical Properties Trust Inc.
The last downgrade for Medical Properties Trust Inc happened on July 2, 2024 when Exane BNP Paribas changed their price target from $6 to $4 for Medical Properties Trust Inc.
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Medical Properties Trust, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Medical Properties Trust was filed on March 12, 2025 so you should expect the next rating to be made available sometime around March 12, 2026.
While ratings are subjective and will change, the latest Medical Properties Trust (MPW) rating was a upgraded with a price target of $5.00 to $9.00. The current price Medical Properties Trust (MPW) is trading at is $5.44, which is within the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.
A newsletter built for market enthusiasts by market enthusiasts. Top stories, top movers, and trade ideas delivered to your inbox every weekday before and after the market closes.